Rupert Bartsch

17PUBLICATIONS
43CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsSolid tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (17)

|Nov 08, 2025
Risk Factors for Disease Recurrence in Patients with HER2+ Early Breast Cancer and Implications for Therapy: A Narrative Review.

Marina E Cazzaniga, Luis Costa, Gilles Freyer

|Aug 05, 2025
HER2/CEP17 ratio predicts residual cancer burden after neoadjuvant dual HER2 blockade: real-world data in patients with primary HER2-amplified breast cancer.

Myriam Stolz, Alex Farr, Kristina A Tendl-Schulz

|May 30, 2025
Patritumab deruxtecan in leptomeningeal metastatic disease of solid tumors: the phase 2 TUXEDO-3 trial.

Matthias Preusser, Javier Garde-Noguera, Juan José García-Mosquera

|Jul 04, 2024
Final outcome analysis from the phase II TUXEDO-1 trial of trastuzumab-deruxtecan in HER2-positive breast cancer patients with active brain metastases.

Rupert Bartsch, Anna Sophie Berghoff, Julia Furtner

|Apr 10, 2023
Frequent Overexpression of HER3 in Brain Metastases from Breast and Lung Cancer.

Erwin Tomasich, Ariane Steindl, Christina Paiato

|Jun 15, 2022
Ovarian Function Suppression: A Deeper Consideration of the Role in Early Breast Cancer and its Potential Impact on Patient Outcomes: A Consensus Statement from an International Expert Panel.

Bolivar Arboleda, Rupert Bartsch, Evandro de Azambuja

Pageof 3

Frequent Collaborators

4 joint publications

Matthias Preusser

2 joint publications

Maximilian Marhold

2 joint publications

Anna Sophie Berghoff

2 joint publications

Georg Widhalm